Bruno Lucidi is Life Sciences Expert at Wallonia Export Investment Agency (AWEX), Expert for the European Commission Horizon 2020, Board director at Atea Inc. and Advisor to Biopharmaceutical companies and Investors.
Bruno Lucidi is an international leader with extensive experience in global corporate strategy. He has shaped and implemented global strategies for companies such as Bristol-Myers Sq
uibb, Johnson and Johnson and GlaxoSmithKline.
Bruno Lucidi’s previous positions include roles such as CEO of Karolinska Development, Aprea and Akinion, Vice-President Pediatric vaccines at GSK, worldwide Vice-President Virology & Oncology at Johnson & Johnson, Chairman of the board of Pharmasset and CEO of Idenix.